Table 2.
Hazard Ratiosa for Death From Prostate Cancer Among Low- and Intermediate-Risk Prostate Cancer Patients in the National Prostate Cancer Register and the ProMort Study, Sweden, 1998–2011
| Variable | NPCR | ProMortb | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariable | Multivariable | Univariable | Multivariable | |||||
| HRc | 95% CI | HRd | 95% CI | HRc | 95% CI | HRd | 95% CI | |
| Age group, years | ||||||||
| ≤55.0 | 0.92 | 0.62, 1.36 | 0.99 | 0.67, 1.47 | 1.03 | 0.64, 1.66 | 1.07 | 0.63, 1.82 |
| 55.1–65.0 | 1.00 | Referent | 1.00 | Referent | 1.00 | Referent | 1.00 | Referent |
| 65.1–75.0 | 2.87 | 2.46, 3.36 | 2.56 | 2.19, 2.99 | 3.12 | 2.53, 3.86 | 2.90 | 2.32, 3.63 |
| >75.0 | 9.15 | 7.84, 10.68 | 7.02 | 5.97, 8.25 | 10.34 | 8.23, 13.00 | 8.06 | 6.26, 10.38 |
| PSA level, ng/mL | ||||||||
| <4.0 | 1.00 | Referent | 1.00 | Referent | 1.00 | Referent | 1.00 | Referent |
| 4.0–9.9 | 1.40 | 1.15, 1.70 | 1.28 | 1.05, 1.57 | 1.22 | 0.92, 1.63 | 0.99 | 0.72, 1.35 |
| ≥10.0 | 2.91 | 2.39, 3.54 | 1.83 | 1.48, 2.25 | 2.60 | 1.94, 3.48 | 1.43 | 1.03, 1.98 |
| Gleason score | ||||||||
| ≤6 | 1.00 | Referent | 1.00 | Referent | 1.00 | Referent | 1.00 | Referent |
| 7 | 2.99 | 2.71, 3.29 | 2.17 | 1.95, 2.40 | 3.04 | 2.56, 3.59 | 2.23 | 1.84, 2.72 |
| Tumor stagee | ||||||||
| T1a | 1.21 | 0.95, 1.55 | 0.96 | 0.75, 1.24 | 1.40 | 1.00, 1.95 | 0.79 | 0.52, 1.20 |
| T1b | 2.87 | 2.29, 3.60 | 1.67 | 1.32, 2.12 | 3.84 | 2.59, 5.70 | 2.25 | 1.49, 3.41 |
| T1c | 1.00 | Referent | 1.00 | Referent | 1.00 | Referent | 1.00 | Referent |
| T2 | 2.61 | 2.35, 2.91 | 1.74 | 1.56, 1.95 | 3.00 | 2.54, 3.54 | 1.83 | 1.51, 2.23 |
Abbreviations: CI, confidence interval; HR, hazard ratio; NPCR, National Prostate Cancer Register; ProMort, Prognostic Factors for Mortality in Prostate Cancer; PSA, prostate-specific antigen.
a Univariable and multivariable flexible parametric proportional hazards models.
b Duplicate observations (n = 150) were excluded from the analysis.
c Adjusted for the matching variables (year and county of diagnosis) but not for any other predictor of prostate cancer mortality.
d Adjusted for the matching variables (year and county of diagnosis).
e Subjects with a nonsubclassified T1 stage (NPCR: n = 60 (2 cases and 58 controls); ProMort: n = 3 (2 cases and 1 control)) were excluded from the analysis.